SAEs · stable COPD
Triple therapy showed no clear difference in all‐cause SAEs compared with LABA/LAMA combination (low certainty).
1 finding from 1 review
Symptoms of dyspnoea · stable COPD
Triple therapy probably leads to higher symptom score TDI, ≥ 1‐unit increase (lower scores indicate worse… compared with LABA/LAMA combination (moderate certainty).
1 finding from 1 review
Change in baseline trough FEV1 · stable COPD
Triple therapy may leads to higher lung function, change in trough FEV1 (mL) compared with LABA/LAMA combination (low certainty).
1 finding from 1 review
Mortality (all‐cause) · stable COPD
Triple therapy may leads to lower mortality (all‐cause) compared with LABA/LAMA combination (low certainty).
1 finding from 1 review
Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · adults and adolescents with asthma
1 finding from 1 review
Mean exacerbations requiring a course of oral corticosteroids · adults and adolescents with asthma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Asthma control · adults and adolescents with asthma
1 finding from 1 review
Unscheduled healthcare utilisation ‐ number of hospital or GP/ED visits · adults and adolescents with asthma
1 finding from 1 review
Anxiety · adults and adolescents with asthma
1 finding from 1 review
Depression at endpoint · adults and adolescents with asthma
1 finding from 1 review
Adherence · adults and adolescents with asthma
1 finding from 1 review
Hospital admissions due to exacerbations: number of participants · adults with asthma not well controlled on ICS
160/4.5 mcg BDF single inhaler therapy showed no clear difference in patients with exacerbations causing hospitalisation compared with current best practice (low certainty).
1 finding from 1 review
Rate of exacerbations requiring systemic corticosteroids · adults with asthma not well controlled on ICS
160/4.5 mcg BDF single inhaler therapy probably leads to lower patients with exacerbations treated with oral steroids compared with current best practice (moderate certainty).
1 finding from 1 review
Fatal serious adverse events · adults with asthma not well controlled on ICS
160/4.5 mcg BDF single inhaler therapy showed no clear difference in fatal serious adverse events compared with current best practice (low certainty).
1 finding from 1 review
Non‐fatal serious adverse events · adults with asthma not well controlled on ICS
160/4.5 mcg BDF single inhaler therapy showed no clear difference in serious adverse events (non‐fatal) compared with current best practice (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with asthma not well controlled on ICS
160/4.5 mcg BDF single inhaler therapy probably leads to higher discontinuation due to adverse events compared with current best practice (moderate certainty).
1 finding from 1 review
AHI score reduction to below 5 points. · obstructive sleep apnoea
Myofunctional therapy plus nasal washing showed no clear difference in AHI score reduction to below 5 points. compared with nasal washing alone (low certainty).
1 finding from 1 review
AHI score change. · obstructive sleep apnoea
1 finding from 1 review
Sexual satisfaction · Men with COPD
1 finding from 1 review
Effect on later sexual function · Men with COPD
1 finding from 1 review